Benzinga
10 Feb 2026, 16:12 UTC · 35w ago
Verdict
Headline leans bullish. We score PHIO +0.80 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Phio Pharmaceuticals' Phase 1b trial of PH-762 showed an 85% pathological response rate at the highest dose, with complete tumor clearance in four of six responders.
So whatHigh clinical efficacy and complete tumor clearance in a cancer trial are primary catalysts for massive valuation increases in micro-cap biotechs.
More positive than 99% of claims this week
The Safety Monitoring Committee reported no serious adverse events or dose-limiting toxicities across all five dose escalation cohorts.
Continue reading
5 related stories
More positive than 91% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 94% of claims this week
The company expects to have material available for non-human primate studies by March 2026 and plans an FDA submission for clinical study design guidance in Q2 2026.
More positive than 81% of claims this week
Manufacturing of cGMP material is scheduled to commence in the second half of 2026.
More positive than 69% of claims this week
Which stocks this story touches
More positive than 91% of ticker scores this week
Stock surged following positive Phase 1b trial results showing high pathological response and tumor clearance for PH-762.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
−2.3%
Price is moving against the score
$0.8795 vs $0.9000 close before publication (Feb 9) · not market-adjusted
PHIO chart →
